Table 3.
Characteristics of invasive physiology measurements in patients randomized to trimetazidine or standard therapy.
| Variable | TMZ + n = 36 | TMZ − n = 35 | p-value |
|---|---|---|---|
| Pd/Pa prior to PCI | 0.75 ± 0.17 | 0.78 ± 0.16 | 0.586 |
| Pd prior to PCI (mmHg) | 53 ± 17 | 57 ± 13 | 0.311 |
| FFR prior to PCI | 0.67 ± 0.11 | 0.65 ± 0.09 | 0.430 |
| Tmn hyperemia before PCI (s) | 0.44 ± 0.26 | 0.43 ± 0.28 | 0.854 |
| CFR prior to PCI | 2.8 ± 1.3 | 2.5 ± 1.9 | 0.518 |
| IMR prior to PCI | 23 ± 13 | 25 ± 13 | 0.594 |
| Wedge pressure (mmHg) | 10 ± 7 | 14 ± 5 | 0.032 |
| Pd/Pa after PCI | 0.91 ± 0.04 | 0.88 ± 0.07 | 0.370 |
| Pd after PCI (mmHg) | 69 ± 15 | 66 ± 17 | 0.422 |
| Tmn hyperaemia after PCI (s) | 0.27 ± 0.19 | 0.36 ± 0.28 | 0.225 |
| FFR after PCI | 0.89 ± 0.05 | 0.85 ± 0.06 | 0.007 |
| CFR after PCI | 2.1 ± 0.8 | 2.3 ± 1.3 | 0.469 |
| IMR after PCI | 18 ± 9 | 24 ± 12 | 0.028 |
CFR, coronary flow reserve; FFR, fractional flow reserve; IMR, index of microcirculatory resistance anterior descending; Pa, arterial pressure; Pd, distal pressure; Tmn, transit mean time; RCA, right coronary artery; OM, obtuse marginal.